BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32710697)

  • 21. Analysis of the incidence, characteristics, and risk factors of complications during induction chemotherapy in children with high-risk neuroblastoma.
    Du J; Yuan X
    Eur J Pediatr; 2024 Jan; 183(1):185-202. PubMed ID: 37855927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.
    Cai J; Pan C; Tang Y; Chen J; Zhou M; Li B; Xue H; Shen S; Gao Y; Zhang A; Tang J
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1327-1335. PubMed ID: 28283783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
    Schmidt M; Simon T; Hero B; Schicha H; Berthold F
    Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
    Stram DO; Matthay KK; O'Leary M; Reynolds CP; Haase GM; Atkinson JB; Brodeur GM; Seeger RC
    J Clin Oncol; 1996 Sep; 14(9):2417-26. PubMed ID: 8823319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India.
    Radhakrishnan V; Raja A; Dhanushkodi M; Ganesan TS; Selvaluxmy G; Sagar TG
    Indian J Pediatr; 2019 May; 86(5):417-426. PubMed ID: 30778950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
    Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
    Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
    [No Abstract]   [Full Text] [Related]  

  • 28. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.
    Seeger RC; Reynolds CP; Gallego R; Stram DO; Gerbing RB; Matthay KK
    J Clin Oncol; 2000 Dec; 18(24):4067-76. PubMed ID: 11118468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.
    Mossé YP; Deyell RJ; Berthold F; Nagakawara A; Ambros PF; Monclair T; Cohn SL; Pearson AD; London WB; Matthay KK
    Pediatr Blood Cancer; 2014 Apr; 61(4):627-35. PubMed ID: 24038992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma.
    Schrey D; Vaidya SJ; Levine D; Pearson AD; Moreno L
    J Pediatr Hematol Oncol; 2015 Apr; 37(3):e150-3. PubMed ID: 26201036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation.
    Hartmann O; Valteau-Couanet D; Benhamou E; Vassal G; Rubie H; Beaujean F; Lemerle J
    Eur J Cancer; 1997 Oct; 33(12):2126-9. PubMed ID: 9516867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
    Asgharzadeh S; Marachelian A; Villablanca JG; Liu WY; Kennedy R; Sposto R; Naranjo A; Tenney S; Yu AL; Ozkaynak MF; Sondel PM; Park JR; Seeger RC
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29719. PubMed ID: 35441784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.
    Peinemann F; van Dalen EC; Enk H; Berthold F
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010685. PubMed ID: 28840597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
    Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
    Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
    Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
    Hero B; Hunneman DH; Gahr M; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):220-3. PubMed ID: 11464889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of surgery in stage IV neuroblastoma.
    Castel V; Tovar JA; Costa E; Cuadros J; Ruiz A; Rollan V; Ruiz-Jimenez JI; Perez-Hernández R; Cañete A
    J Pediatr Surg; 2002 Nov; 37(11):1574-8. PubMed ID: 12407542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management and outcome of stage 3 neuroblastoma.
    Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
    Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.